6 completed, 3 terminated. 4 Phase 1, 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 2 | Terminated 2 |
Follow tariquidar: new trials by email Literature Review of tariquidar trials Research Report on tariquidar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tariquidar-ondansetron Combination in Neuropathic Pain Ondansetron 16 mg with Tariquidar, Ondansetron 16 mg with Placebo - Neuropathic Pain | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 24 | 2021-01-31 | 2025-08-14 |
| Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar - Neuropathic Pain | Phase 1 | Terminated | Washington University School of Medicine | 14 | 2019-05-20 | 2022-04-07 |
| PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy Tariquidar, Tc-94m Sestamibi - Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2004-05-16 | 2017-08-17 |
| Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer XR9576 (Tariquidar) - Adrenal Cortex Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 50 | 2003-10-01 | 2012-09-18 |
| Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer docetaxel, tariquidar, 99mTc-sestamibi imaging - Lung Neoplasms, Ovarian Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2003-09-01 | 2012-10-12 |
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) Chemotherapy, tariquidar + paclitaxel/carboplatin, placebo + paclitaxel/carboplatin - Stage IIIb Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 3 | Terminated | QLT Inc. | 540 | 2002-06-01 | 2012-05-23 |
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) Chemotherapy, tariquidar + vinorelbine, placebo + vinorelbine - Stage IIIb Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 3 | Terminated | QLT Inc. | 490 | 2002-06-01 | 2012-05-23 |
| Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors Tariquidar - Wilms' Tumor, Sarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2001-02-15 | 2019-07-16 |
| Vinorelbine and XR9576 to Treat Cancer Vinorelbine, XR9576 - Breast Cancer, Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 1999-12-01 | 2008-03-04 |
Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Neuralgia (2) · Ovarian Neoplasms (2) · Adrenal Cortex Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Endocrine Gland Neoplasms (1) · Kidney Neoplasms (1) · Sarcoma (1) · Uterine Cervical Neoplasms (1) · Wilms Tumor (1)
National Cancer Institute (NCI) (5) · QLT Inc. (2) · Washington University School of Medicine (2)
United States (7)
Simon Haroutounian, PhD (2) · Antonio Fojo, M.D. (1) · Brigitte C Widemann, M.D. (1) · Peter Choyke, M.D. (1) · Susan E Bates, M.D. (1)